BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 29327101)

  • 1. Fundamentals of siRNA and miRNA therapeutics and a review of targeted nanoparticle delivery systems in breast cancer.
    Ahmadzada T; Reid G; McKenzie DR
    Biophys Rev; 2018 Feb; 10(1):69-86. PubMed ID: 29327101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficient nanocarriers of siRNA therapeutics for cancer treatment.
    Subhan MA; Torchilin VP
    Transl Res; 2019 Dec; 214():62-91. PubMed ID: 31369717
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cationic liquid crystalline nanoparticles for the delivery of synthetic RNAi-based therapeutics.
    Gentile E; Oba T; Lin J; Shao R; Meng F; Cao X; Lin HY; Mourad M; Pataer A; Baladandayuthapani V; Cai D; Roth JA; Ji L
    Oncotarget; 2017 Jul; 8(29):48222-48239. PubMed ID: 28637023
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RNAi-based therapeutics and tumor targeted delivery in cancer.
    Kara G; Calin GA; Ozpolat B
    Adv Drug Deliv Rev; 2022 Mar; 182():114113. PubMed ID: 35063535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lipid nanocarriers for microRNA delivery.
    Scheideler M; Vidakovic I; Prassl R
    Chem Phys Lipids; 2020 Jan; 226():104837. PubMed ID: 31689410
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Novel approaches in cancer treatment: preclinical and clinical development of small non-coding RNA therapeutics.
    Cuciniello R; Filosa S; Crispi S
    J Exp Clin Cancer Res; 2021 Dec; 40(1):383. PubMed ID: 34863235
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Versatile RNA interference nanoplatform for systemic delivery of RNAs.
    Choi KY; Silvestre OF; Huang X; Min KH; Howard GP; Hida N; Jin AJ; Carvajal N; Lee SW; Hong JI; Chen X
    ACS Nano; 2014 May; 8(5):4559-70. PubMed ID: 24779637
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipid Nanoparticle Technology for Clinical Translation of siRNA Therapeutics.
    Kulkarni JA; Witzigmann D; Chen S; Cullis PR; van der Meel R
    Acc Chem Res; 2019 Sep; 52(9):2435-2444. PubMed ID: 31397996
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nanoparticles for targeted delivery of therapeutics and small interfering RNAs in hepatocellular carcinoma.
    Varshosaz J; Farzan M
    World J Gastroenterol; 2015 Nov; 21(42):12022-41. PubMed ID: 26576089
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A paradigm shift for extracellular vesicles as small RNA carriers: from cellular waste elimination to therapeutic applications.
    Hagiwara K; Ochiya T; Kosaka N
    Drug Deliv Transl Res; 2014; 4(1):31-7. PubMed ID: 24533256
    [TBL] [Abstract][Full Text] [Related]  

  • 11. RNAi-Based Therapeutics and Novel RNA Bioengineering Technologies.
    Traber GM; Yu AM
    J Pharmacol Exp Ther; 2023 Jan; 384(1):133-154. PubMed ID: 35680378
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Endosomolytic and Tumor-Penetrating Mesoporous Silica Nanoparticles for siRNA/miRNA Combination Cancer Therapy.
    Wang Y; Xie Y; Kilchrist KV; Li J; Duvall CL; Oupický D
    ACS Appl Mater Interfaces; 2020 Jan; 12(4):4308-4322. PubMed ID: 31939276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanovehicle-based Small Interfering RNA (siRNA) Delivery for Therapeutic Purposes: A New Molecular Approach in Pharmacogenomics.
    Akhtari J; Tafazoli A; Mehrad-Majd H; Mahrooz A
    Curr Clin Pharmacol; 2018; 13(3):173-182. PubMed ID: 29992895
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Small interfering RNAs based therapies for intracerebral hemorrhage: challenges and progress in drug delivery systems.
    Almarghalani DA; Boddu SHS; Ali M; Kondaka A; Ta D; Shah RA; Shah ZA
    Neural Regen Res; 2022 Aug; 17(8):1717-1725. PubMed ID: 35017419
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effective tools for RNA-derived therapeutics: siRNA interference or miRNA mimicry.
    Wang P; Zhou Y; Richards AM
    Theranostics; 2021; 11(18):8771-8796. PubMed ID: 34522211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current development of targeted oligonucleotide-based cancer therapies: Perspective on HER2-positive breast cancer treatment.
    Ngamcherdtrakul W; Castro DJ; Gu S; Morry J; Reda M; Gray JW; Yantasee W
    Cancer Treat Rev; 2016 Apr; 45():19-29. PubMed ID: 26930249
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Folate Receptor-Mediated siRNA Delivery: Recent Developments and Future Directions for RNAi Therapeutics.
    Gangopadhyay S; Nikam RR; Gore KR
    Nucleic Acid Ther; 2021 Aug; 31(4):245-270. PubMed ID: 33595381
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Progress in microRNA delivery.
    Zhang Y; Wang Z; Gemeinhart RA
    J Control Release; 2013 Dec; 172(3):962-74. PubMed ID: 24075926
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.